UK boasts of investment as cell and gene therapy trials rise

8 January 2019
cellandgenetherapycatapult-big

The government-backed Cell and Gene Therapy (CGT) Catapult has boasted that the UK’s pipeline of advanced therapy medicinal products continues to go from strength to strength.

There are currently 85 clinical trials and 875 pre-clinical research projects in cell and gene therapies ongoing in the UK, representing a 37% and 20% increase year-on-year respectively.

"We are building the world’s most complete advanced therapies ecosystem"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology